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Angiotensin II–Induced Nox2-Mediated
Reactive Oxygen Species*Tetsuro Ago, MD, PHD,y Junichi Sadoshima, MD, PHDzSEE PAGE 261R eactive oxygen species (ROS) are pro-duced primarily in mitochondria as by-products of oxidative phosphorylation.
However, enzymes also actively produce ROS (1).
The NADPH oxidase (nicotinamide adenine dinucleo-
tide phosphate oxidase, or Nox) family proteins are
unique in that they are dedicated to producing super-
oxide and H2O2. Nox2, also known as gp91phox, and
Nox4 are the major Nox isoforms in the heart. Both
Nox2 and Nox4 form a heterodimer with p22phox at
either plasma or intracellular membranes, whereas
Nox2 also associates with cytosolic activators,
p47phox, p67phox, and Rac1/2, for its full activation.
In the healthy heart, ROS are promptly eliminated
by powerful intracellular antioxidant mechanisms,
including superoxide dismutase (SOD), catalase,
and peroxiredoxin (2). However, excessive accumu-
lation of ROS, caused by either up-regulation of
ROS-producing enzymes or down-regulation of
antioxidants under myocardial stress, induces
myocardial injury and promotes heart failure. Nox
proteins are often up-regulated in response to stress,
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this paper to disclose.producing mechanisms, thereby promoting mito-
chondrial “ROS-induced ROS release” to exacerbate
overall oxidative stress in many pathological condi-
tions in the heart (3).
Importantly, however, increasing lines of evidence
suggest that the Nox family proteins also play phys-
iological or adaptive roles in some conditions. For
example, stretch-induced production of ROS (X-ROS)
by Nox2 at the junctional sarcoplasmic reticulum
(SR) mediates mechano-chemo transduction by
sensitizing the ryanodine receptor (RyR2) in healthy
cardiomyocytes (4) (Figure 1A). The physiological
level of ROS produced by either Nox2 or Nox4 is
required for HIF-1a activation, which is essential
for cardiomyocytes to survive during ischemia/
reperfusion (5). Generally, these cellular functions
are mediated by a limited amount of ROS, which
are produced locally and modulate their targets
post-translationally, thereby acting as signaling
molecules.ANGIOTENSIN II–INDUCED NOX2-ROS
In this issue of the Journal, Zhang et al. (6) reported
an unexpected function of Nox2-mediated ROS in the
heart. Using transgenic mice with cardiomyocyte-
speciﬁc overexpression of Nox2 (Tg-CM-Nox2), the
authors studied the short-term effects of a subpressor
dose of angiotensin II (Ang II) on contractile function
in the heart and the cardiomyocytes therein. Whereas
Tg-CM-Nox2 showed no obvious cardiac phenotype
at baseline, the transgenic mouse heart exhibited
signiﬁcantly increased contractility with more rapid
calcium (Ca2þ) reuptake and enhanced Ca2þ release in
FIGURE 1 Speculated Mechanisms Underlying Nox2-ROS–Mediated Contractile Enhancement
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(A) Stretch-induced production of reactive oxygen species (ROS) from nicotinamide adenine dinucleotide phosphate oxidase (Nox2) at the
junctional sarcoplasmic reticulum (SR) enhances calcium (Ca2þ) sensitivity by sensitizing the ryanodine receptor (RyR2) in healthy car-
diomyocytes. Stretch-induced Nox2-ROS may not reach phosphatase-1/phospholamban (PP1/PLN) because of the action of antioxidants, such
as peroxiredoxin (Prx). (B) Angiotensin II (Ang II) type 1 receptor (AT1R) may activate Nox2 located far apart from the junctional SR. Alter-
natively, stretch and Ang II may activate distinct populations of receptor tyrosine kinases (RTKs), which in turn lead to inactivation of Prx
located in distinct subcellular spaces. Thus, Ang II–induced Nox2-ROS, but not stretch, can suppress PP-1 activity, thereby enhancing phos-
phorylation of PLN and SERCA2 activation. LTCC ¼ L-type calcium channel; P ¼ phosphorylation at Ser-16; PKA ¼ protein kinase A; SERCA2 ¼
sarcoplasmic reticulum Ca2þ-ATPase 2.
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275response to Ang II, causing faster contraction and
relaxation. In Tg-CM-Nox2 mice, phosphorylation of
phospholamban (PLN) at Ser-16 was signiﬁcantly
increased in response to Ang II. PLN is an endogenous
inhibitor of sarcoplasmic reticulum Ca2þ-ATPase 2
(SERCA2), which is itself inhibited upon PLN phos-
phorylation at Ser-16 (7). This phosphorylation is
mediated by protein kinase A, whereas it is de-
phosphorylated by protein phosphatase-1 (PP-1), a
serine/threonine phosphatase (7). The authors
showed that Ang II inhibited PP-1 activity through
Nox2-ROS and proposed that PP-1 suppression medi-
ates the increased PLN phosphorylation, its dissocia-
tion from SERCA2, and the increased contractile
activity in cardiomyocytes (Figure 1B). Although there
is a report showing that cysteine oxidation of PP-1
inhibits its activity, oxidation-reduction (redox)-
mediated regulation of serine/threonine phospha-
tases appears to be less common than that of protein
tyrosine phosphatase (8,9). Thus, a possibility re-
mains that other mechanisms play a more important
role in mediating the effect of Nox2 upon increases in
cardiac contractility.
ANG II RECEPTOR, NOX2, AND
PP-1/PLN/SERCA2 COMPLEX
Superoxide produced by Nox2 is rapidly converted
to H2O2 by SOD. Although H2O2 may travel across the
plasma membrane, the powerful reducing environ-
ment inside normal cells limits the distance it can
travel. Thus, regulated post-translational modiﬁca-
tion of cellular targets by ROS may be achieved only
in highly compartmentalized environments or in the
presence of deliberate inactivation of speciﬁc anti-
oxidants, such as tyrosine phosphorylation of per-
oxiredoxin, an antioxidant that reduces H2O2 (10).
For example, X-ROS–induced sensitization of RyR2 is
mediated by Nox2 localized at junctional SR (4)
(Figure 1A). Thus, in order for ROS produced by
Ang II–induced activation of Nox2 to act on PP-1/PLN
located in the SR, the Ang II type 1 receptor and
Nox2 and its cytosolic activators should be localized
in close proximity to PP-1/PLN (Figure 1B). Zhang
et al. (6) showed that Nox2 is localized on the
membranes around the T-tubule in cardiomyocytes.
Although this suggests that Nox2 on the T-tubules is
responsible for regulating PP-1/PLN, elucidation of
the precise localization of Nox2 and demonstration
of the local production of ROS around the T-tubule
would substantiate the proposed mechanism.
Furthermore, it is puzzling how stretch allows
coupling between Nox2 on the junctional SR andRyR2 (4) (Figure 1A), whereas Ang II induces
coupling between the Nox2 on the T-tubule and PP-
1/PLN (Figure 1B). One explanation could be that
stretch and Ang II activate Nox2 located far apart.
Another possibility is that stretch and Ang II may
activate distinct populations of receptor tyrosine
kinases, such as epidermal growth factor receptors,
which in turn leads to inactivation of the H2O2-
reducing antioxidant peroxiredoxin located in
distinct subcellular spaces (Figure 1B). This would
allow stretch and Ang II to create distinct subcellular
compartments for Nox2 to modulate distinct targets
(11,12).
ANG II–MEDIATED
PATHOLOGICAL HYPERTROPHY
Ang II activates Nox2 by facilitating complex forma-
tion between Nox2 and its cytosolic activators while
also up-regulating Nox2 (13). Cardiac hypertrophy
after the infusion of a subpressor dose of Ang II for 2
weeks was attenuated in mice with systemic deletion
of Nox2. Thus, endogenous Nox2 is involved posi-
tively in the development of Ang II–induced hyper-
trophy (13). Endogenous Nox2 also plays an essential
role in mediating cardiac dysfunction and interstitial
ﬁbrosis in response to pressure overload (14). These
results suggest that Nox2 is involved in the develop-
ment of pathological hypertrophy and heart failure in
response to long-term stimulation with Ang II or
mechanical forces.
On the basis of the results of Zhang et al. (6), Nox2
promotes increases in cardiac contractility, at least in
the short term. However, endogenous Nox2 also me-
diates the long-term development of pathological
hypertrophy and progression of cardiac failure. How,
then, does Ang II–induced activation of Nox2 mediate
these contrasting functions?
A possible explanation: long-term exposure of
Ang II up-regulates Nox2 and down-regulates anti-
oxidants, thereby inducing higher levels of ROS
compared with short-term exposure (15). When ROS
reach a certain level, Nox2 participates in a positive
feedback mechanism of ROS production. Addition-
ally, reduced activities of antioxidants may disturb
the compartmentalization of Nox2-derived ROS and
abolish physiological functions of Nox2 while exac-
erbating known ROS pathological functions, such
as mitochondrial damage, ER stress, and deoxy-
ribonucleic acid damage and eventual cell death
(Figure 2). Interestingly, Tg-CM-Nox2 mice exhibited
a greater extent of cardiac hypertrophy in response
to Ang II. The authors did not investigate whether
FIGURE 2 Possible Cardiac Effects of Ang II–Induced Nox2-ROS
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(A) Short-term and subpressor doses of Ang II may induce increased cardiac contractility and adaptive hypertrophy through physiological
amounts of ROS. (B) Alternatively, long-term Ang II may induce excessive amounts of ROS through extreme enhancement of Nox2 and down-
regulation of antioxidant activities, and may abolish physiological functions of Nox2 and exacerbate known pathological functions of ROS,
leading to heart failure. Nox2 in noncardiomyocytes, such as vascular cells and ﬁbroblasts, may also mediate pathological hypertrophy pro-
gression. Abbreviations as in Figure 1.
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pathological. Although the authors showed that
short-term pressure overload exacerbates cardiac
dysfunction in Tg-CM-Nox2 mice, given the poten-
tial difference in the Nox2 coupling between Ang II
and stretch, it would be interesting to further
investigate whether longer treatment of Tg-CM-Nox2
with Ang II induces pathological hypertrophy and, if
so, whether it is also mediated by PP-1 suppression.
Notably, the previously conducted Nox2 loss-of-
function study that used systemic Nox2 knockout
mice did not address Nox2 cell type–speciﬁc actions.
Thus, it is formally possible that Ang II–induced acti-
vation of Nox2 in cardiomyocytes could be adaptive
even after long-term stimulation with Ang II. Inter-
estingly, Ang II induces cardiac hypertrophy with a
more pathological phenotype in transgenic mice with
endothelial cell-speciﬁc overexpression of Nox2
compared with Tg-CM-Nox2, suggesting that Nox2 in
noncardiomyocytes mediates pathological hypertro-
phy (16) (Figure 2). Further studies are required to
elucidate whether the Nox2 function switches from
adaptive to maladaptive in response to long-term Ang
II application, and if so, the underlying mechanism by
which Nox2 mediates such dichotomous functions.Zhang et al. (6) have discovered a novel physio-
logical function of Nox2 in cardiomyocytes, which
mediates increased contractility in response to Ang
II. Further investigation regarding the underlying
molecular mechanism may lead to the development
of a novel intervention to stimulate cardiac con-
tractility without the known harmful effects of
Nox2 in the heart. Suppression of Nox2 prevents
cardiac hypertrophy, attenuates the development of
heart failure, and inhibits ischemia/reperfusion
injury. However, if Nox2 inhibition is to be
considered for treating heart disease, it appears
to be important not to inhibit Nox2 excessively
so that physiological functions of Nox2 are not
abolished.
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